Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ASHP suggests early removal of CFC-containing MDIs

Executive Summary

The American Society of Health-System Pharmacists suggests that six of the seven asthma and chronic obstructive pulmonary disease drugs flagged by FDA as no longer essential, and thus no longer exempt from regulations banning the use of chlorofluorocarbons, should be removed from the market by Dec. 31, 2008, instead of 2009 as proposed. FDA issued the proposed rule to remove the essential-use designation from seven drugs used in metered-dose inhalers that the agency has tentatively determined have therapeutically equivalent non-ozone-depleting alternatives (1"The Pink Sheet" June 11, 2007, p. 23). ASHP's sole exception is Maxiar Autohaler (pirbuterol), for which it recommends a removal date later than 2009. Other drugs in the proposed rule are those containing flunisolide, triamcinolone, metaproterenol, perbuterol, cromolyn, nedocromil and albuterol and ipratropium in combination. Comment on the rule has been extended to September 10, 2007...
Advertisement

Related Content

Advertisement
UsernamePublicRestriction

Register

PS048737

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel